gastric cancer gastric carcinoma
Conditions
Interventions
Every patient included in this study will receive 4 courses of chemotherapy
consisting of Taxotere, Xeloda and Cisplatin
Sponsors
Jeroen Bosch Ziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Ib-IVa histological proven resectable gastric adenocarcinoma, including gastro-oesophageal junction/cardia carcinoma Siewert 2 and 3 WHO or equal to 18 years No prior radio- or chemotherapy conflicting with the treatment of gastric cancer
Exclusion criteria
Exclusion criteria: Ia gastric cancer Other histological type than adenocarcinoma Distant metastases Inoperable patients Previous or other current malignancies Other current serious illness or medical conditions Pregnant or lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Assessment of the feasibility and toxicity efficacy/response rate (down-sizing/down-staging) of the combination of 4 courses of docetaxel/Taxotere*, cisplatin and capecitabine/Xeloda* as neoadjuvant chemotherapy in resectable localized or locally advanced gastric cancer - Percentage of patients who completed 4 courses of chemotherapy and proceeded to surgery - Surgical quality control in resectable gastric cancer - Establishment of toxicity and safety profile - Assessment of the reduction of tumour load with CT (or PET-CT) after neoadjuvant chemotherapy | — |
Secondary
| Measure | Time frame |
|---|---|
| - Introduction of a D1extra-resection as the standard surgical treatment - Percentage of complete pathological response - Percentage of complete pathological resection - Assessment of quality of life after treatment with neo-adjuvant chemotherapy and surgery in local or locally advanced gastric carcinoma | — |
Countries
Netherlands
Outcome results
None listed